Min Yan

13PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 19, 2026
Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.

|Sep 29, 2026
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).

|Jun 19, 2025
Distress thermometer and determinants of psychological distress in metastatic breast cancer.

Huihui Sun, Huimin Lv, Limin Niu

|May 09, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun

|Apr 22, 2025
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Dechuang Jiao, Jianghua Qiao, Xianfu Sun

|Jan 02, 2025
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.

Ying Fan, Qingyuan Zhang, Min Yan

Pageof 3

Frequent Collaborators

4 joint publications

Zhenzhen Liu

4 joint publications

Binghe Xu

3 joint publications

Xiaojia Wang

3 joint publications

Shusen Wang